文献速递糖尿病

早发2型糖尿病的大血管病变与死亡风险的时间趋势:英国初级保健电子病历研究

Temporal Trend in Young-Onset Type 2 Diabetes-Macrovascular and Mortality Risk: Study of U.K. Primary Care Electronic Medical Records.
PubMed 文献 · Diabetes Care · 2020-07-02

基于英国初级保健数据库2000至2017年新诊断2型糖尿病患者370,854例,评估早发与常规发病2型糖尿病的动脉粥样硬化性心血管疾病(ASCVD)和全因死亡(ACM)风险。早发患者中肥胖、高HbA1c和高LDL-C比例高而心脏保护治疗使用率低,且无论诊断时心血管代谢风险高低,ASCVD和ACM风险相似;指南需通过前瞻性研究重新评估。

要点

  • 2000至2017年英国初级保健数据库新诊断2型糖尿病370,854例,按年龄组和诊断时有无ASCVD病史及高风险状态分析。
  • 18-39岁组71%肥胖、HbA1c 8.6%、71%高LDL-C,仅18%使用心脏保护治疗,23%为高风险。
  • 18-39岁组高风险与低风险者至ASCVD/ACM调整平均年数相似,而≥50岁组高风险者事件更早。

核心结论

  • 与常规发病不同,早发2型糖尿病无论诊断时心血管代谢风险因素状态如何,心血管和死亡风险相似。
  • 作者认为,关于早发2型糖尿病强化风险因素管理和心脏保护治疗的指南需通过前瞻性研究紧急重新评估。

研究设计与样本

  • 研究基于英国初级保健数据库,纳入2000至2017年新诊断2型糖尿病患者370,854例。
  • 按年龄组(18-39、40-49、50-59、60-69、70-79岁)及诊断时无ASCVD病史的高/低风险状态分析,当前吸烟、高收缩压、高LDL-C或慢性肾病中两项及以上者为高风险。

主要发现

  • 诊断时年龄<50岁者比例在2000至2010年间增加后趋于稳定。
  • 年龄≥50岁者ASCVD和ACM发病率下降,而<50岁者未下降。
  • 与≥50岁者相比,诊断时18-39岁者肥胖比例更高(71%肥胖)、HbA1c更高(8.6%),71%有高LDL-C,仅18%接受心脏保护治疗。
  • 18-39岁组中2%诊断时已有ASCVD,23%被确定为高风险。
  • 18-39岁组高风险者至ASCVD/ACM的调整平均年数(9.1年[95% CI 8.2-10.0]/9.3年[8.1-10.4])与低风险者(10.0年[9.5-10.5]/10.5年[9.7-11.2])相似;≥50岁高风险者较低风险组ASCVD事件早约1.5-2年、死亡早约1.1-1.5年(P < 0.01)。

临床怎么用

  • 作者认为,早发2型糖尿病强化风险因素管理和心脏保护治疗的指南需通过前瞻性研究紧急重新评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate temporal prevalence trend, cardiometabolic risk factors, and the risk of atherosclerotic cardiovascular disease (ASCVD) and all-cause mortality (ACM) in incident young- and usual-onset type 2 diabetes. RESEARCH DESIGN AND METHODS: From the U.K. primary care database, 370,854 people with a new diagnosis of type 2 diabetes from 2000 to 2017 were identified. Analyses were conducted by age-group (18-39, 40-49, 50-59, 60-69, 70-79 years) and high-/low-risk status without history of ASCVD at diagnosis, with subjects with two or more of current smoking, high systolic blood pressure, high LDL cholesterol (LDL-C), or chronic kidney disease classified as high risk. RESULTS: The proportion of people aged <50 years at diagnosis increased during 2000-2010 and then stabilized. The incidence rates of ASCVD and ACM declined in people aged ≥50 years but did not decrease in people <50 years. Compared with people aged ≥50 years, those aged 18-39 years at diagnosis had a higher proportion of obesity (71% obese) and higher HbA1c (8.6%), and 71% had high LDL-C, while only 18% were on cardioprotective therapy. Although 2% in this age-group had ASCVD at diagnosis, 23% were identified as high risk. In the 18-39-year age-group, the adjusted average years to ASCVD/ACM in high-risk individuals (9.1 years [95% CI 8.2-10.0]/9.3 years [8.1-10.4]) were similar to the years in those with low risk (10.0 years [9.5-10.5]/10.5 years [9.7-11.2]). However, individuals aged ≥50 years with high risk were likely to experience an ASCVD event 1.5-2 years earlier and death 1.1-1.5 years earlier compared with low-risk groups (P < 0.01). CONCLUSIONS: Unlike usual-onset, young-onset type 2 diabetes has similar cardiovascular and mortality risk irrespective of cardiometabolic risk factor status at diagnosis. The guidelines on the management of young-onset type 2 diabetes for intensive risk factor management and cardioprotective therapies need to be urgently reevaluated through prospective studies.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Koye DN, Ling J, Dibato J, et al. Temporal Trend in Young-Onset Type 2 Diabetes-Macrovascular and Mortality Risk: Study of U.K. Primary Care Electronic Medical Records. Diabetes Care. 2020. PMID: 32616608. doi:10.2337/dc20-0417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。